OSCOR acquired by INTEGER
Context
Integer Holdings has successfully finalized the acquisition of Oscor, Inc., a strategic move designed to significantly broaden the group’s cardiovascular and neurostimulation product portfolios. This transaction integrates a robust range of proprietary products, including steerable sheaths and cardiac leads, into the acquirer’s existing medical device outsource framework. The strategic rationale for the move centers on the acquisition of specialized technical capabilities and a vast intellectual property portfolio that deepens relationships with existing Tier 1 customers while providing access to emerging growth companies. By incorporating the target’s established brand and its research and development expertise, the organization bolsters its "concept-to-commercialization" value proposition. A key component of the integration is the addition of the target’s manufacturing presence in the Dominican Republic, which provides high-efficiency, low-cost production capacity to support the group’s global expansion. This partnership reinforces the group’s standing as a primary technical enabler for the cardiac rhythm management and neuromodulation industries, ensuring the strategic depth required to exceed market growth rates in fast-growing clinical segments like structural heart and electrophysiology.
OSCOR, which reported an EBITDA margin of in 2020, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Oscor is a specialized medical technology organization dedicated to the design, development, and manufacturing of highly engineered implantable devices and venous access systems. The entity’s business model is centered on a "concept-to-commercialization" framework, providing a comprehensive line of finished introducer systems, guiding sheaths, and proprietary lead wire technologies. Its value proposition lies in its deep technical expertise in cardiac pacing, electrophysiology, and neurostimulation, serving both established medical device giants and emerging growth companies. Strategically, the firm focuses on high-growth clinical markets such as structural heart and peripheral vascular interventions. By maintaining vertically integrated operations—including research and development and industrialized manufacturing—the organization ensures technical durability and precision in mission-critical components. The entity facilitates the rapid deployment of complex medical solutions through its extensive intellectual property portfolio and specialized manufacturing footprint.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (USD)
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 01/2022 | ARDIAN | BIOFARMA GROUP | ITALY | CDMO |
| 01/2022 | ANJAC BEAUTY & HEALTH | APOLLO HEALTHCARE CORP. | CANADA | CDMO |
| 12/2021 | PLANMECA GROUP | KAVO DENTAL | GERMANY | Medical Devices |
| 12/2021 | THE CARLYLE GROUP / GTCR | RESONETICS | UNITED STATES | Medical Devices |
| 12/2021 | WINNCARE | PHARMAOUEST INDUSTRIES | FRANCE | Medical Devices |
| 11/2021 | COLOPLAST | ATOS MEDICAL | SWEDEN | Medical Consumables |
| 09/2021 | PERRIGO COMPANY | HRA PHARMA | FRANCE | Generics / Labs |
| 07/2021 | MONTAGU PRIVATE EQUITY | INTECH MEDICAL | FRANCE | Implants & Prosthetics |
| 07/2021 | PARTNERS GROUP | PHARMATHEN | GREECE | CDMO |
| 07/2021 | ORKLA | NUTRAQ | Norway | Nutrition & Dietary Supplements |
REFERENCES
Valuation range: EV 100M - 350M USD
Revenue range: 50M - 100M USD
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of OSCOR by INTEGER are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.